While we may pursue an initial business combination target in any industry or sector, geography, or stage of its corporate evolution, we do not currently contemplate targeting a company in the fossil fuel energy industry, including the upstream, midstream and energy services sub-sectors, and we intend to focus our search in North America, Europe or […]

 We currently intend to focus on high-growth software and technology-enabled companies that are disrupting large and established industries and markets.  The members of our management team are associated with the Pritzker Vlock Family Office, a multi-billion-dollar family office that invests in companies and their management teams with industry changing ideas, as well as LaunchCapital, a […]

We are a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Our goal is to transform the treatment paradigm for patients suffering from these potentially life-threatening conditions for which there are no approved medicines or where existing approved medicines have […]

We are a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. We developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries and fits in the palm of a hand.  We believe the novel coronavirus, or COVID-19, pandemic has […]

We are an advertising software company. Our software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. Programmatic advertising is rapidly taking market share from traditional ad sales channels, which require more staffing, offer less transparency and involve higher costs to buyers. Our demand side platform (“DSP”), Adelphic, is […]

We are a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. NASH is a severe form of non-alcoholic fatty liver disease, or NAFLD, that affects up to 15 million people in the United States, and up to 6% of the global population, for […]

We are a late-stage biotechnology company pioneering the development of a novel class of TCR (T cell receptor) bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging our proprietary, flexible, off-the-shelf ImmTAX platform, we are developing a deep pipeline in multiple therapeutic areas, including […]

Note: This is the third blank-check company put together by Barry S. Sternlicht, the founder and former chairman and CEO of Starwood Hotels & Resorts Worldwide. (This blank-check company is incorporated in the Cayman Islands.) From the prospectus: Our sponsor, Mustang Sponsor LLC, is an affiliate of Jaws Estates Capital, the family office of Barry S. […]

We are a clinical-stage immunotherapy company engaged in the discovery and development of next-generation therapies with an initial focus on treatments for cancer. Our proprietary ImmunoPhage platform is a powerful, self-adjuvanted and highly differentiated immunotherapy approach that is designed to utilize bacteriophage to induce a robust, focused and coordinated innate and adaptive immune response. We […]

We are a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Our proprietary Boltbody Immune-Stimulating Antibody Conjugate, or ISAC, approach is pioneering a new category of immunotherapies that combines the precision of antibody targeting with the immune system’s strength by activating and recruiting myeloid cells to […]